Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | OGA | O60502 | 14/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25589849 | 0.85 | HRH4 (0.48) | ACHELMNAALDH1A1 | |
| SCHEMBL24590204 | 0.80 | POLB (0.49) | OGALMNAKDM4EALDH1A1MAPT | |
| SCHEMBL890101 | 0.79 | OGA (0.55) | PTPN11ACHEOGAKDM4EALDH1A1 | |
| SCHEMBL17897245 | 0.77 | OGA (0.56) | PTPN11OGAKDM4EALDH1A1MAPT | |
| SCHEMBL1743222 | 0.77 | PANK3 (0.47) | PTPN11ACHEOGAKDM4EALDH1A1 | |
| SCHEMBL1126338 | 0.77 | OGA (0.53) | PTPN11ACHEOGAKDM4EALDH1A1 | |
| SCHEMBL889353 | 0.77 | OGA (0.45) | PTPN11ACHEOGAKDM4EALDH1A1 | |
| SCHEMBL83122 | 0.77 | OGA (0.50) | PTPN11ACHEOGAKDM4EALDH1A1 | |
| SCHEMBL18334115 | 0.75 | OGA (0.58) | PTPN11OGAKDM4EALDH1A1MAPT | |
| SCHEMBL21419379 | 0.75 | OGA (0.46) | PTPN11ACHEOGAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216513-A1 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | FASN, FABP1, SCD | PTPN11 4543/4885ACHE 4049/4885OGA 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.